Colonisation with vancomycin- and linezolid-resistant Enterococcus faecium in a university hospital: molecular epidemiology and risk factor analysis

International Journal of Antimicrobial Agents

Volumn 33, Issue 2, 2009, Pages 137-142

  Souli, Maria ^a   Sakka, Vissaria ^a   Galani, Irene ^a   Antoniadou, Anastasia ^a   Galani, Lambrini ^a   Siafakas, Nikolaos ^a   Zerva, Loukia ^a   Fytrou, Helen ^a   Tsiodras, Sotirios ^a   Giamarellou, Helen ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Antimicrobial resistance; Environmental contamination; Esp; VRE

Indexed keywords

AMPICILLIN; CARBAPENEM; CEFTOBIPROLE; CEPHALOSPORIN; CIPROFLOXACIN; DALFOPRISTIN PLUS QUINUPRISTIN; GENTAMICIN; GLYCOPEPTIDE; IMIPENEM; LEVOFLOXACIN; LINEZOLID; MINOCYCLINE; MONOBACTAM; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; QUINOLONE DERIVATIVE; TEICOPLANIN; TIGECYCLINE; VANCOMYCIN;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL COLONIZATION; CLINICAL ARTICLE; CONTROLLED STUDY; ENTEROCOCCUS FAECIUM; FEMALE; HOSPITALIZATION; HUMAN; IMMUNE DEFICIENCY; MALE; MOLECULAR EPIDEMIOLOGY; MOLECULAR TYPING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PULSED FIELD GEL ELECTROPHORESIS; RISK FACTOR; UNIVARIATE ANALYSIS; UNIVERSITY HOSPITAL;

ACETAMIDES; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CARRIER STATE; DNA FINGERPRINTING; ELECTROPHORESIS, GEL, PULSED-FIELD; ENTEROCOCCUS FAECIUM; ENVIRONMENTAL MICROBIOLOGY; EPIDEMIOLOGY, MOLECULAR; FECES; FEMALE; GENOTYPE; GRAM-POSITIVE BACTERIAL INFECTIONS; GREECE; HOSPITALS, UNIVERSITY; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; OXAZOLIDINONES; POINT MUTATION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; RISK FACTORS; RNA, BACTERIAL; RNA, RIBOSOMAL, 23S; VANCOMYCIN RESISTANCE;

EID: 58149180087     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2008.08.017     Document Type: Article

References (35)

1. Prystowsky J., Siddiqui F., Chosay J., Shinabarger D.L., Millichap J., Peterson L.R., et al. Resistance to linezolid: characterization of mutations in rRNA and comparison of their occurrences in vancomycin-resistant enterococci. Antimicrob Agents Chemother 45 (2001) 2154-2156
2. Tsiodras S., Gold H.S., Sakoulas G., Eliopoulos G.M., Wennersten C., Venkataraman L., et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 358 (2001) 207-208
3. Meka V.G., and Gold H.S. Antimicrobial resistance to linezolid. Clin Infect Dis 39 (2004) 1010-1015
4. Marshall S.H., Donskey C.J., Hutton-Thomas R., Salata R.A., and Rice L.B. Gene dosage and linezolid resistance in Enterococcus faecium and Enterococcus faecalis. Antimicrob Agents Chemother 46 (2002) 3334-3336
5. Sakka V., Tsiodras S., Galani L., Antoniadou A., Souli M., Galani I., et al. Risk-factors and predictors of mortality in patients colonised with vancomycin-resistant enterococci. Clin Microbiol Infect 14 (2008) 14-21
6. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Fifteenth informational supplement. M100-S15. Wayne, PA: CLSI; 2005.
7. Tenover F.C., Arbeit R.D., Goering R.V., Mickelsen P.A., Murray B.E., Persing D.H., et al. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol 33 (1995) 2233-2239
8. Woodford N., Tysall L., Auckland C., Stockdale M.W., Lawson A.J., Walker R.A., et al. Detection of oxazolidinone-resistant Enterococcus faecalis and Enterococcus faecium strains by real-time PCR and PCR-restriction fragment length polymorphism analysis. J Clin Microbiol 40 (2002) 4298-4300
9. Werner G., Klare I., Fleige C., and Witte W. Increasing rates of vancomycin resistance among Enterococcus faecium isolated from German hospitals between 2004 and 2006 are due to wide clonal dissemination of vancomycin-resistant enterococci and horizontal spread of vanA clusters. Int J Med Microbiol 298 (2008) 515-527
10. Zurenko G, Todd WM, Hafkin BA. Development of linezolid-resistant Enterococcus faecium in two compassionate use program patients treated with linezolid. In: 39th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 26-29 September 1999, San Francisco, CA. Washington, DC: ASM Press; 1999. Abstract 848, p. 118.
11. Gonzales R.D., Schreckenberger P.C., Graham M.B., Kelkar S., DenBesten K., and Quinn J.P. Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid. Lancet 357 (2001) 1179
12. Johnson A.P., Tysall L., Stockdale M.V., Woodford N., Kaufmann M.E., Warner M., et al. Emerging linezolid-resistant Enterococcus faecalis and Enterococcus faecium isolated from two Austrian patients in the same intensive care unit. Eur J Clin Microbiol Infect Dis 21 (2002) 751-754
13. Auckland C., Teare L., Cooke F., Kaufmann M.E., Warner M., Jones G., et al. Linezolid-resistant enterococci: report of the first isolates in the United Kingdom. J Antimicrob Chemother 50 (2002) 743-746
14. Bassetti M., Farrel P.A., Callan D.A., Topal J.E., and Dembry L.M. Emergence of linezolid-resistant Enterococcus faecium during treatment of enterococcal infections. Int J Antimicrob Agents 21 (2003) 593-594
15. Swoboda S., Fritz S., Martignoni M.E., Feldhues R.A., Hoppe-Tichy T., Buchler M.W., et al. Varying linezolid susceptibility of vancomycin-resistant Enterococcus faecium isolates during therapy: a case report. J Antimicrob Chemother 56 (2005) 787-789
16. Seedat J., Zick G., Klare I., Konstabel C., Weiler N., and Sahly H. Rapid emergence of resistance to linezolid during linezolid therapy of an Enterococcus faecium infection. Antimicrob Agents Chemother 50 (2006) 4217-4219
17. Jones R.N., Della-Latta P., Lee L.V., and Biedenbach D.J. Linezolid-resistant Enterococcus faecium isolated from a patient without prior exposure to an oxazolidinone: report from the SENTRY antimicrobial surveillance program. Diagn Microbiol Infect Dis 42 (2002) 137-139
18. Rahim S., Pillai S.K., Gold H.S., Venkataraman L., Inglima K., and Press R.A. Linezolid-resistant, vancomycin-resistant Enterococcus faecium infection in patients without prior exposure to linezolid. Clin Infect Dis 36 (2003) 146-148
19. Bonora M.G., Solbiati M., Stepan E., Zorzi A., Luzzani A., Catania M.R., et al. Emergence of linezolid resistance in the vancomycin-resistant Enterococcus faecium multilocus sequence typing C1 epidemic lineage. J Clin Microbiol 44 (2006) 1153-1155
20. Dobbs T.E., Patel M., Waites K.B., Moser S.A., Stamm A.M., and Hoesley C.J. Nosocomial spread of Enterococcus faecium resistant to vancomycin and linezolid in a tertiary care medical center. J Clin Microbiol 44 (2006) 3368-3370
21. Herrero I.A., Issa N.C., and Patel R. Nosocomial spread of linezolid-resistant vancomycin-resistant Enterococcus faecium. N Engl J Med 346 (2002) 867-869
22. Kainer M.A., Devasia R.A., Jones T.F., Simmons B.P., Melton K., Chow S., et al. Response to emerging infection leading to outbreak of linezolid-resistant enterococci. Emerg Infect Dis 13 (2007) 1024-1030
23. Boyce J.M. Environmental contamination makes an important contribution to hospital infection. J Hosp Infect 65 (2007) 50-54
24. Bhalla A., Pultz N.J., Gries D.M., Ray A.J., Eckstein E.C., Aron D.C., et al. Acquisition of nosocomial pathogens on hands after contact with environmental surfaces near hospitalized patients. Infect Control Hosp Epidemiol 25 (2004) 164-167
25. Duckro A.N., Blom D.W., Lyle E.A., Weinstein R.A., and Hayden M.K. Transfer of vancomycin-resistant enterococci via health care worker hands. Arch Intern Med 165 (2005) 302-307
26. Drees M., Snydman D.R., Schmid C.H., Barefoot L., Hansjosten K., Vue P.M., et al. Prior environmental contamination increases the risk of acquisition of vancomycin-resistant enterococci. Clin Infect Dis 46 (2008) 678-685
27. Hayden M.K., Bonten M.J., Blom D.W., Lyle E.A., van de Vijver D.A., and Weinstein R.A. Reduction in acquisition of vancomycin-resistant Enterococcus after enforcement of routine environmental cleaning measures. Clin Infect Dis 42 (2006) 1552-1560
28. Byers K.E., Durbin L.J., Simonton B.M., Anglim A.M., Adal K.A., and Farr B.M. Disinfection of hospital rooms contaminated with vancomycin-resistant Enterococcus faecium. Infect Control Hosp Epidemiol 19 (1998) 261-264
29. Klare I., Konstabel C., Mueller-Bertling S., Werner G., Strommenger B., Kettlitz C., et al. Spread of ampicillin/vancomycin-resistant Enterococcus faecium of the epidemic-virulent clonal complex-17 carrying the genes esp and hyl in German hospitals. Eur J Clin Microbiol Infect Dis 24 (2005) 815-825
30. Pai M.P., Rodvold K.A., Schreckenberger P.C., Gonzales R.D., Petrolatti J.M., and Quinn J.P. Risk factors associated with the development of infection with linezolid- and vancomycin-resistant Enterococcus faecium. Clin Infect Dis 35 (2002) 1269-1272
31. Scheetz M.H., Knechtel S., Malczynski M., Postelnick M.J., and Qi C. Increasing incidence of linezolid-intermediate or -resistant, vancomycin-resistant Enterococcus faecium strains parallels increasing linezolid consumption. Antimicrob Agents Chemother 52 (2008) 2256-2259
32. Willems R.J.L., and Bonten M.J.M. Glycopeptide-resistant enterococci: deciphering virulence, resistance and epidemicity. Curr Opin Infect Dis 20 (2007) 384-390
33. Leavis H.L., Willems R.J., Van Wamel W.J., Schuren F.H., Caspers M.P., and Bonten M.J. Insertion sequence-driven diversification creates a globally dispersed emerging multiresistant subspecies of Enterococcus faecium. PLoS Pathog 3 (2007) 75-96
34. Deshpande L.M., Fritsche T.R., Moet G.J., Biedenbach D.J., and Jones R.N. Antimicrobial resistance and molecular epidemiology of vancomycin-resistant enterococci from North America and Europe: a report from the SENTRY antimicrobial surveillance program. Diagn Microbiol Infect Dis 58 (2007) 163-170
35. ® annual appraisal of potency and spectrum program results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from 16 countries. Diagn Microbiol Infect Dis 59 (2007) 199-209